Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial

Overview of attention for article published in Lancet Neurology, March 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)

Mentioned by

twitter: 8 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 148 Mendeley

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 68,835 followers.

RT @academiamir: El hierro influye en el daño secundario tras hemorragias cerebrales. Ya han comprobado la seguridad del mesilato de defero…

El hierro influye en el daño secundario tras hemorragias cerebrales. Ya han comprobado la seguridad del mesilato de deferoxamina (quelante), ¿pero evitará el daño secundario? 👇 #ictus #Medicina https://t.co/CFCmlpkSlf

RT @NatRevNeurol: Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled,…

RT @PittStroke: Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, do…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 4 additional X posts.